Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression
Retrieved on:
金曜日, 5月 31, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Traffic barrier, Lung, Principal, Progression-free survival, Patient, Diarrhea, Anaplastic lymphoma kinase, Headache, Cough, Weight gain, Learning, Hypercholesterolemia, Risk, Hypertriglyceridemia, Inc., Lung cancer, Doctor of Philosophy, Arthralgia, PFS, Disease, Edema, NSCLC, APLS, Death, Peripheral neuropathy, HR, Abstract, Periodic breathing, Hypertension, PFE, ASCO, Journal, Brain, Society, ALK, Confidence interval, Aes, MBBS, Crizotinib, Pharmaceutical industry
Further, 60% of patients treated with LORBRENA (95% CI, 51-68) were alive without disease progression after five years compared to 8% (3-14) on the XALKORI treatment arm.
Key Points:
- Further, 60% of patients treated with LORBRENA (95% CI, 51-68) were alive without disease progression after five years compared to 8% (3-14) on the XALKORI treatment arm.
- “These results from the CROWN trial are unprecedented, as the majority of patients on LORBRENA are living beyond five years without disease progression,” said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer.
- “This updated analysis shows that LORBRENA helped patients live longer without disease progression, with the majority of patients experiencing sustained benefit for over five years, including nearly all patients having protection from progression of disease in the brain.
- At the time of analysis, 50% of patients in the CROWN trial were still receiving LORBRENA compared to 5% of patients receiving XALKORI.